Monday, March 21, 2022
Onconova Therapeutics (ONTX)
Full-Year Financial Report Included Strong Pipeline Progress
Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.
Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Onconova Reported FY2021 and Updated Its Clinical Trials In Progress. Onconova reported a loss of $16.2 million or $(0.96) per share for FY2021. Importantly, the company reiterated its development schedule for the announcement of clinical data and the start of new clinical trials. Cash on hand on December 31, 2021 was $55.1 million or $2.64 per share.
Narazaciclib Continues Patient Treatment In Its Dose Escalation Trials. Narazaciclib is currently in two trials testing increasing doses and different administration schedules. The US trial is enrolling patients in its fourth cohort dosed at 160 mg once daily. The China trial is testing its fifth cohort at 200mg in cycles of daily dosing for three weeks followed by one week off. Data from these …
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.